Medicus Pharma Ltd. 8K

Medicus Pharma Inc. entered into a global co‑development and license agreement with Pfizer Inc. for CD228V (PF‑08046031), involving substantial upfront, milestone, royalty, and transaction‑share economics and shifting primary development and commercialization responsibility to Medicus while Pfizer retains certain rights and a future funding option.

Medicus Pharma Inc. entered into a comprehensive Co‑Development and License Agreement with Pfizer Inc., effective September 2, 2026, under which Pfizer grants Medicus an exclusive, sublicensable, royalty‑bearing license to Pfizer’s CD228V (PF‑08046031/SGN‑CD228V) product‑specific patent rights and a non‑exclusive license to related platform patents and know‑how worldwide for human use, while retaining certain internal research and comparator-use rights. Medicus assumes primary responsibility and cost for development, regulatory approval, manufacturing, and commercialization globally, subject to commercially reasonable efforts obligations, structured development planning and reporting, and rights for Pfizer to review and comment but not control decisions. As consideration, Medicus will pay Pfizer a US$12 million upfront fee on the effective date and a US$15 million first‑anniversary payment, reimburse specified material transfer costs, and owes Pfizer tiered development milestone payments by indication, annual and cumulative sales milestone payments tied to Net Sales thresholds, running royalties based on marginal Net Sales tiers (subject to reductions where no valid patent claim exists), and a defined share of sublicensing income and strategic transaction proceeds. Pfizer will make a one‑time US$2 million development funding payment to Medicus, strictly earmarked for development activities under the plan and subject to audit, and holds an option, upon initiation of pivotal trials or third‑party funding arrangements, to negotiate additional post‑pivotal development funding. The agreement also details sublicensing parameters, information transfer, tax and payment mechanics, record‑keeping and audit rights, and preserves Pfizer’s ability to use residual know‑how and to supply CD228V for limited non‑GMP research purposes.

Filing Facts

CIK

1997296

Ticker

-

Form

8K

Source Type

sec

Accession

0001062993-26-004806

Alert Tier

8